• June 3-6, 2024
  • San Diego Convention Center, California



Ceria Therapeutics, Inc.

Monday, June 03, 2024
Platform for Therapeutics
Company Presentation Theater 4
Ceria Therapeutics, Inc. is a preclinical biopharmaceutical company headquartered in Tucson AZ and founded in 2019. The company is developing products derived from a platform technology yielding in development for conditions in the critical care, GI, and wound care markets, collectively addressing >$25B market opportunities in the US. Each of Ceria’s products delivers and restores a naturally-occurring RNA molecule (microRNA-146a) that plays a critical role in regulating inflammation. Our products transiently increase this molecule in inflamed tissues resulting in rapid blocking of cytokines and durable resolution of disease in acute conditions characterized by dysregulated inflammation. Our critical care assets address acute lung injury, acute respiratory distress syndrome, acute kidney injury, acute pancreatitis, and toxemic sepsis. Our GI assets address Crohn's disease and ulcerative colitis and our dermatology assets address non-healing diabetic foot ulcers.
Ceria Therapeutics, Inc.
Company Website: https://www.ceriatx.com
Lead Product in Development: CTX-002 is being developed as a host-directed therapeutic to treat acute lung injuries (ALI) and acute respiratory distress syndrome (ARDS).
Number Of Unlicensed Products (For Which You Are Seeking Partners): CTX-001- injectable drug for treatment of advanced diabetic foot ulcers, currently being manufactured. IND filing - 2025. CTX-003 - oral treatment for inflammatory bowel disease, currently in formulation studies. IND filing - 2026. CTX-004 - topical treatment of early-stage diabetic foot ulcers, currently in formulation studies. IND filing - 2025. CTX-005 - (medical device) topical cream for the prevention of decubitus ulcers (pressure ulcers). 510(k) pathway, filing TBD.

Company HQ City


Company HQ State


Company HQ Country

United States

CEO/Top Company Official

David M Jackson PhD, CEO

Development Phase of Primary Product

Primary Speaker
David Jackson, PhD
Ceria Therapeutics, Inc.
Back to Session List


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.